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Summary.-A system is proposed by the UICC for assessing response to treatment
of advanced breast cancers.
IN 1975, a project was initiated by the
Programme on Clinical Oncology of the
UICC to formulate a system for the
evaluation of response to treatment of
advanced cancer. It was considered that
a single uniform system, used inter-
nationally, would be invaluable for the
accurate comparison of published results
from different centres. Advanced breast
cancer was selected as the first tumour for
consideration, because a number of dif-
ferent evaluation methods was already in
use (Hayward, 1966; British Breast Group,
1974; Segaloff, 1966; Eastern Co-operative
Oncology Group, unpub.; Rozeneweig and
Heuson, 1975; Breast Cancer Group in
Japan, 1973), and it was felt that agree-
ment on a common system might readily
be achieved. A preliminary document
describing such a system was prepared,
and was then circulated to many workers
in the field for comment, after which it was
revised accordingly. The final document
is now presented. It is hoped that this
system will be widely adopted and that it
may eventually be used as a model for the
assessment of therapy of other tumours.
It has been accepted by the British Breast
Group and replaces its previously pub-
lished assessment method (British Breast
Group, 1974).
1. Aim
These guidelines are intended for use in
designing clinical trials to assess the
objective response of locally advanced or
metastatic mammary cancer to treatment;
subjective response to treatment is not
considered.
2. Criteria of eligibility
2.1. Histological evidence ofbreast cancer
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2.2. Objective evidence of progression of
disease, i.e. newlesions appearorexisting
lesions become larger.
2.3. Bulk of clinical disease must be
evaluable by either direct measurement
or photography and/or radiography.
3. Exclusions
3.1. It is recognized that many factors
may affect a patients ability to tolerate
specific therapy. The following should,
therefore, be considered in the selection
of patients for study:
3.1. 1. Debility.
3.1.2. Associated medical conditions.
3.1. 3. Previous antitumour therapy
(especially chemotherapy and radio-
therapy).
3.1.4. Other previous or concurrent treat-
ment.
3.2. The following are factors which
seriously compromise the evaluation of
results and lead to the exclusion of
patients from a study of systemic
therapy:
3.2.1. Previous or current malignancies
at other sites, with the exception of
cone-biopsied in situ carcinoma of the
cervix uteri and adequately treated
basal or squamous cell carcinoma ofthe
skin.
3.2.2. Patients in whom one of the fol-
lowing is the sole manifestation of
disease:
lymphoedema
hilar enlargement
pleural effusion
ascites
metastases in the central nervous system
marrow suppression
osteoblastic skeletal lesions.
3. 2.3. Previous systemic antitumour
treatment with the agent(s) understudy.
3.2.4. In order to avoid confusion with a
withdrawal response or a delayed re-
sponse to treatment, it is suggested that
patients within 4 weeks of endocrine
ablation or cessation of additive hor-
mone therapy be excluded. In the case
of long-acting hormones or depot pre-
parations, this period may have to be
increased. When previous chemo-
therapy or radiotherapy has been used,
the toxic manifestations of these treat-
ments, which affect subsequent specific
therapy, must have resolved. After 4
weeks the patient can be included only
if there is evidence of progressive
disease.
4. Baseline studies
4.1. History.-A standard history should
be obtained in all cases, with special
attention to:
4.1.1. Stage of primary disease at the
time of initial presentation, expressed
if possible in the TNM Classification
(International Union Against Cancer,
1974), and its histology and pathological
extent.
4.1.2. Recording of race, dates of birth,
diagnosis of breast cancer and last
menstrual period.
4.1.3. The extent and date of treatment
of the primary tumour and the time of
first recurrence should be noted. The
date of first recurrence should be given
as the time of documentation of the
first sign, not symptom, confirmed
subsequently to be a recurrence.
4.1.4. Dates, agents and the recorded
result ofprevious treatment ofrecurrent
breast cancer.
4.1.5. Concurrent diseases.
4.1.6. Other past and present treatment.
4.2. Performance.-An estimation of per-
formance may be an important part of
evaluation. The Karnofsky system
(Karnofsky and Burchenal, 1948) would
be appropriate, or the following 5-grade
system could be used:
GRADE PERFORMANCE
0 Fully active, able to carry on
all usual activities without
restriction and without the aid
ofanalgesia.
1 Restricted in strenuous acti-
vity but ambulatory and able
to carry out light work or
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pursue a sedentary occupation.
Also patients who are fully
active, as in Grade 0, but only
with the aid of analgesics.
2 Ambulatory and capable of all
self-care but unable to work.
Up and about more than 50%
ofwaking hours.
3 Capable of only limited self-
care, confined to bed or chair
more than 50% of waking
hours.
4 Completely disabled, unable to
carry out any self-care and
confined totally to bed or chair.
4.3. Physical examination.-Before start-
ing new treatment, a full physical
examination including measurement of
height and weight should be done on all
patients. Special attention should be
directed to tissues or organs where
toxic manifestations oftreatment might
be expected to develop.
Superficial and palpable lesions
should be measured directly (in cm)
along 2 axes-one being thelongest, and
the other, thelongestperpendicular toit.
Callipers may improve the accuracy of
the measurements.
4.4. Photographs.-Colour photographs of
all visible lesions, together with identifi-
cations, date and cm rule should be
taken.
4.5. Radiographs.-The following sites
should be radiographed for baseline
informationwithstandardizedexposures
ifpossible:
chest
skull
total spine
pelvis
femora
and an isotopic bone scan should be
done.
4.6. Laboratory studies.-Because thera-
peutic agents and/or cancer may affect
normal function, appropriate investi-
gations should be carried out to evaluate
cardiac, pulmonary, metabolic, hepatic,
renal, endocrine and marrow status
before treatment is started.
4. 7. Additional studies.-When appropri-
ate and feasible, the following might be
helpful:
--radio-isotope scans of brain, bone
and liver
computerized axial transverse (CAT)
scans
mammography
bone marrow biopsy
- laparoscopy
- thoracoscopy
- hormone receptor assays
- potential markers of disease, e.g.
CEA, HCG, dimethyl-guanosine
- ultra-sonography
- immunological evaluation
- hydroxyproline excretion
5. Measurements of lesions
Normally this will be by physical
examination, photography orradiography.
5.1. Breast.-Measurements should be
made as in 4.3 and superficial lesions
should be photographed. Measurements
from mammography may be useful.
Diffuse infiltration of the breast is
difficult to assess. It is recommended
that cutaneous marks be made 10 cm
apart, centred on the nipple. The
distance between these marks is meas-
ured after digital compression of the
breast and recorded as " compression
at 10 cm = x cm ".
5.2. Skin.-Individual lesions should be
measured as in 4.3. Diffuse lesions
should be recorded by photography.
5.3. Lymph nodes.-(a) Superficial nodes:
if possible, measurements as in 4.3,
otherwise in one dimension. Xero-
radiography may be helpful.
(b) Mediastinal nodes: chest X-ray,
tomograms. Generally, comparison of
mediastinal size during treatment may
be possible by comparing radiographs,
and the width ofthe mediastinum could
be taken as a unidimensional measure-
ment at a stated level. The site of
mediastinal nodes should be confirmed
by a lateral chest X-ray.
(c) Lymphoedema: measurement of
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limb circumference at a stated level
above and below the olecranon.
5.4. Bone. An assessment of skeletal
involvement should be made, and indi-
vidual lesions can be evaluated from
selected films. Comparison of sequen-
tial bone scans may provide additional
information. It should be noted that
other processes can produce increased
uptake of radionucleides in bone scans,
and that both progression and regres-
sion of lesions may be reflected by an
increase in uptake.
5.5. Lung.-(a) Nodular: measurement
in 2 dimensions from radiograph
whenever possible.
(b) Diffuse: this should be evaluated and
compared from serial chest X-rays. It
is recognized that comparisons may
sometimes be difficult.
5.6. Pleural effusion. Pleural effusion
should be recorded by chest X-rays (PA
and lateral). Frequency and volume of
thoracenteses should be noted.
5.7. Liver.-Histological confirmation of
hepatic metastases is desirable when
this is the only site ofrecurrence.
Clinical measurement of the liver
should be done with the patient in the
supine position. The inferior border
of the liver should be measured as a
vertical distance below the costal mar-
gin or xiphisternal notch, at a fixed
distance from the mid-line and/or at the
mid-line. The same reference point
must be used at all examinations in the
same patient. The phase of respir-
ation should also be the same. This
will normally be either quiet respiration
or deep inspiration. It should be
remembered that the presence of a right
pleural effusion and its subsequent
aspiration can affect apparent liver size.
Sequential liver scans can be used for
comparison.
5.8. Ascites.-The girth of the abdomen
should be measured at a fixed point.
Weight should be recorded periodically.
Frequency and volume of required
abdominal paracenteses and the use of
diuretics should be noted. Increased
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adiposity may make serial measure-
ments invalid. Ultrasonography and
CAT scans may provide additional
information.
5.9. Abdominal mass. Measurement in
2 dimensions with callipers where pos-
sible. If feasible, ultra-sound and CAT
scans should be done.
5.10. Nervous system.-Neurological defi-
cit will be recorded in the physical
examination, but should not be used to
quantify response. Sequential CAT
scans may be useful.
6. Recording of lesions
This should be done by anatomical
site. Dimensions should be stated when
applicable and the method of evaluation
stated (direct measurement, photograph,
radiograph, or other).
It is recognized that pleural effusion,
ascites, hepatomegaly, pulmonary
shadows, etc., may be the result of non-
malignant processes. When possible, his-
tological proof of involvement should be
obtained, if these abnormalities are to be
used for evaluation of response or strati-
fication.
6.1. Soft tissue
Breast ipsilateral
contralateral
Skin -intracutaneous
subcutaneous
Lymphoedema
Lymphatic location stated; medi-
astinal and intra-abdominal nodes ex-
cluded here (see 6.3).
6.2. Bone.
Sites recorded
(state whether lytic and/or blastic).
6. 3. Visceral.
Lung (nodular or diffuse)
Pleura (nodules and/or malignant effu-
sion)
Mediastinal and intra-abdominal nodes
Liver
Ascites
Abdominal or pelvic masses
Central nervous system.
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7. Stratification
Controlled trials are important in
clinical research. Although randomiza-
tion eliminates bias and selection on the
part of the investigator, considerable
disparity between groups under study can
still arise. Even when no disparity arises,
the comparison of treatment can be made
more precise by taking prognostic vari-
ables into account in the statistical
analysis. It is recommended that patients
should be classified according to certain
factors known to influence prognosis or
response to therapy. These factors can
be used to stratify patients, using a
system of allocation which balances num-
bers allotted to different treatments with-
in each stratum; alternatively, with non-
stratified allocation, they can be used as a
basis for statistical analysis of the results
of the trial. The factors chosen will
depend on the treatment under study.
The following may be considered.
7.1. Menopausal status.-There are 3
physiological categories of menopausal
status which may be classified in various
ways. The following is suggested:
7.1.1. Pre-menopausal-a menstrual
period has occurred within the previous
year.
7.1.2. Early post-menopausal-last
period: 1-5 years.
7.1.3. Latepost-menopausal-last period
> 5 years ago.
Women who have had a hysterectomy
with one or both ovaries left in place may
be excluded, or considered pre-meno-
pausal if < 50 years of age, and post-
menopausal if > 55 years of age (7.1.3);
those aged 50-55 years are classified as
7.1.2. Vaginal cytology and/or hormone
studies may clarify the true menopausal
status. Young women who have had an
artificial menopause should be excluded or
considered separately.
7.2. Disease-free interval.-(i.e. time from
treatment ofprimary tumourbysurgery
or radiotherapy to time of first recur-
rence; see 4.1.2.).
7.2.1. No free interval.
7.2.2. < 2 years.
7.2.3. 3 2 years.
All patients presenting with Stage IV
(Ml) disease have no free interval.
Patients receiving radiotherapy as the sole
treatment of the primary tumour should
be stratified separately.
7.3. Other groups.-When appropriate,
other factors can be chosen for stratifi-
cation, e.g. site of disease, age, per-
formance, histological grade, previous
therapy, residual toxicity, hormone
receptors, immune status etc.
8. Follow-up studies
8.1. The standard follow-up time for
patients under study will normally be
4 weeks, but it is recognized that, for
specific protocols (e.g. chemotherapy),
this may have to be modified. How-
ever, it is important that each group in
a controlled study be evaluated regu-
larly at similar intervals.
8.2. Baseline studies should be repeated
regularly, at intervals of not more than
6 months, unless symptoms develop
which demand earlier examination.
8.3. Photographs should be repeated
every 3 months or sooner if changes
occur.
9. Definition of response
9.1. Measurable lesions.-Ideally, all
lesions should be measured at each
assessment. When multiple lesions are
present, this may not be possible and,
under such circumstances, a repre-
sentative number of 8 or more lesions
may be selected for measurement.
9.1.1. In the case ofbidimensional lesions
regression will be defined as when
either:
(i) all lesions disappear
(ii) the sum of the products of the dia-
meters of each individual lesion, or
those selected for study, decreases by
50% or more, with no lesion increasing
in size.
In either case, no new lesions should
appear.
296RESPONSE TO THERAPY IN ADVANCED BREAST CANCER
Progression is defined as when
either:
(i) new lesions appear
(ii) there is a 25% or more increase in
the sum ofthe products ofthe diameters
of each lesion measured, except that if
an increase of less than 25% makes
additional treatment necessary, this is
also regarded as progression.
9.1.2. For unideminsional lesions. in the
case of regression the same rules apply
as in 9.1.1, except that regression is
taken as a decrease of 50% or more in
the one measurement. In situations
such as infiltration of the breast, liver
involvement, and mediastinal enlarge-
ment, objective regression is a 50% or
greater decrease in that measurement
which is regarded as being in excess of
that usual for the site under consider-
ation.
9.2. Evaluable, but non-measurable lesions.
-(e.g. osseous metastases, pulmonary
infiltration, pleural effusion, skin infil-
tration). Serial evidence ofappreciable
change documented by radiography or
photography must be obtained and be
available for subsequent review. The
assessment must always be objective.
Pathological fractures or collapse of
bones are not necessarily evidence of
progressive disease.
Neither the development norhealing
of skin ulcers should be taken as sole
evidence ofchange.
10. Categories of response
10.1. Objective regression.
10.1.1. Complete response.-disappea-
rance of all known disease. In the case
of lytic bone metastases, these must be
shown radiologically to have calcified.
10.1.2. Partial response.-3 50% de-
crease inmeasurable lesions as definedin
9.1.1 and 9.1.2, and objective im-
provement in evaluable, but non-mea-
surable lesions. No new lesions. It is
not necessary for every lesion to have
regressed to qualify for partial response,
but no lesion should have progressed.
10.2. Nochange.-Lesions unchanged (i.e.
< 50% decrease or < 25% increase in
the size of measurable lesions).
Note: If non-measurable but evalu-
able lesions represent the bulk ofdisease
and these clearly do not respond, even
though measurable lesions have im-
proved, this is considered as "no
change " not " objective regression
10.3. Progressive disease.
10.3.1. Mixed.-some lesions regress
while others progress or new lesions
appear.
10.3.2. Failure.-progression of some or
all lesions and/or appearance of new
lesions. No lesions regress.
11. Duration of response
In a patient who has an objective
regression, this is to be dated from the
start of therapy until either new lesions
appear or any one existing lesion increases
by 25% or more above its smallest size
recorded.
It is essential to categorize a patient as
having a regression at a stated time. It is
also essential that all baseline studies
should have been repeated at this time.
12. Survival
Survival, dated from time of com-
mencement of treatment to death, should
be recorded.
13. Extra-mural review
It is recommended that the records of
all patients under study be assessed by
extra-mural reviewers.
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